Skip to Content
Merck
CN

D7071

Dapoxetine hydrochloride

≥98% (HPLC)

Synonym(s):

(S)-N,N-dimethyl-1-phenyl-3-(1-naphthalenyloxy)propanamine hydrochloride, S-(+)-N,N-dimethyl-a-[2-(naphthalenyloxy)ethyl] benzenemethanamine hydrochloride, LY-210448 hydrochloride

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C21H23NO · HCl
CAS Number:
129938-20-1
Molecular Weight:
341.87
NACRES:
NA.77
PubChem Substance ID:
329798842
UNSPSC Code:
12352200
MDL number:
MFCD08272809

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

InChI

1S/C21H23NO.ClH/c1-22(2)20(18-10-4-3-5-11-18)15-16-23-21-14-8-12-17-9-6-7-13-19(17)21;/h3-14,20H,15-16H2,1-2H3;1H/t20-;/m0./s1

SMILES string

Cl.CN(C)[C@@H](CCOc1cccc2ccccc12)c3ccccc3

InChI key

IHWDIQRWYNMKFM-BDQAORGHSA-N

assay

≥98% (HPLC)

form

powder

optical activity

[α]/D +125 to +135°, c = 1 in methanol

storage condition

desiccated

color

white

solubility

DMSO: ≥20 mg/mL

originator

Eli Lilly

storage temp.

room temp

Quality Level

100

Gene Information

human ... SLC6A4(6532)

General description

Dapoxetine ((+)-(S)-N,N-dimethyl-(α)-[2(1naphthal enyloxy)ethyl]-benzenemethanamine hydrochloride) possess a similar structure as that of fluoxetine.

Biochem/physiol Actions

Dapoxetine is capable of blocking recombinant Kv4.3 potassium voltage-gated channels. It is considered as safe.
Potent Selective serotonin reuptake inhibitor (SSRI); used in treatment of premature ejaculation
Potent and selective SSRI

Features and Benefits

This compound is featured on the Biogenic Amine Transporters page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Eli Lilly. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

pictograms

Exclamation mark
GHS07

signalword

Warning

Hazard Classifications

Acute Tox. 4 Oral - Aquatic Chronic 4 - Eye Irrit. 2

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Regulatory Information

新产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000362275
0000362275
0000257055
0000250041
0000257055

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

W J G Hellstrom
International journal of clinical practice, 65(1), 16-26 (2010-12-16)
Current and upcoming treatment options for premature ejaculation (PE) are of global clinical interest. In 2008, the International Society for Sexual Medicine published an evidence-based definition for PE. While there are no US Food and Drug Administration-approved therapies for PE
Chris G McMahon
Expert opinion on pharmacotherapy, 11(10), 1741-1752 (2010-06-15)
Premature ejaculation (PE) is a common male sexual disorder which is associated with substantial personal and interpersonal negative psychological factors. Drug treatment of PE with an off-label antidepressant selective serotonin reuptake inhibitor (SSRI) drug is common. The lack of an
Hartmut Porst
The journal of sexual medicine, 8 Suppl 4, 335-341 (2011-10-14)
With increasing interest and clinical research in male sexual disorders, it has become clear that not only psychological but also organic, neurobiological, and genetic factors may play an important role in premature ejaculation (PE). This article provides an overview of
Shiwei Tang et al.
Advances in therapy, 36(8), 2096-2105 (2019-05-31)
Factors that impact the pharmacokinetics of dapoxetine, a 5-HT selective reuptake inhibitor used for the treatment of premature ejaculation, have not been clearly identified. This study aimed to evaluate the effects of consumption of a high-fat meal and cytochrome P450
Nicola Mondaini et al.
Urology, 82(3), 620-624 (2013-08-31)
To assess both the acceptance and the discontinuation rates from dapoxetine, the first oral pharmacological agent indicated for the treatment of premature ejaculation (PE). One hundred twenty consecutive potent patients (mean age 40.3 years; range 18-63 years) seeking medical treatment
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service